Literature DB >> 16444994

Evaluation of tumor FDG transport and metabolism in primary central nervous system lymphoma using [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) kinetic analysis.

Nobuyuki Kawai1, Yoshihiro Nishiyama, Keisuke Miyake, Takashi Tamiya, Seigo Nagao.   

Abstract

OBJECTIVE: Although 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has been used as a promising tool to diagnose primary central nervous system lymphoma (PCNSL) because the tumor shows very high FDG accumulation, no data exist evaluating the extent of tumor FDG transport and metabolism. The aim of this study was to evaluate the feasibility of FDG-PET kinetic analysis in measurement of uptake parameters of FDG in the lymphoma tissues and in the assessment of treatment effects in patients with PCNSL.
METHODS: Dynamic FDG-PET examination was performed in 7 histologically proven PCNSL patients before and after methotrexate-based chemotherapy.
RESULTS: Before the chemotherapy, the highest CMRglc in the tumor for all 7 patients was 79.4 +/- 27.2 micromol/100 g/min. This value was significantly higher than that observed in the normal cortex in 14 control patients (44.3 +/- 6.0 micromol/100 g/min, p < 0.001). The phosphorylation (k3) activity was also significantly higher in the tumor (0.093 +/- 0.026 min(-1)) compared with the normal cortex (0.064 +/- 0.014 min(-1), p < 0.05). On the other hand, the transporter (K1) activity in the tumor (0.079 +/- 0.016 ml/min) was similar to that observed in the normal cortex (0.082 +/- 0.012 ml/min). The chemotherapy significantly reduced the volume of the tumor in 6 of 7 patients and the highest CMRglc in the tumor examined 18.0 +/- 5.5 days after the chemotherapy (34.0 +/- 21.8 micromol/100 g/min) was significantly lower than that observed before the chemotherapy (p < 0.01). This reduction in FDG uptake was concomitant with a significant reduction in both the K1 and k3 values (p < 0.05). The reduction in the k3 value after the chemotherapy was marked in 6 of 7 patients in whom the tumor responded to the first chemotherapy.
CONCLUSIONS: Dynamic image acquisition can separate regional FDG uptake into FDG transport and phosphorylation activity in the lymphoma tissues. Tumor FDG uptake was significantly higher with accelerated phosphorylation activity compared with that observed in the normal cortex.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16444994     DOI: 10.1007/BF02985117

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  8 in total

1.  18F-FDG PET/CT in primary brain lymphoma.

Authors:  Domenico Albano; Giovanni Bosio; Mattia Bertoli; Raffaele Giubbini; Francesco Bertagna
Journal:  J Neurooncol       Date:  2017-11-17       Impact factor: 4.130

2.  Prognostic value of pretreatment 18F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment.

Authors:  Nobuyuki Kawai; Hai-Ning Zhen; Keisuke Miyake; Yuka Yamamaoto; Yoshihiro Nishiyama; Takashi Tamiya
Journal:  J Neurooncol       Date:  2010-11       Impact factor: 4.130

3.  Correlation between positron emission tomography findings and glucose transporter 1, 3 and L-type amino acid transporter 1 mRNA expression in primary central nervous system lymphomas.

Authors:  Yoshinobu Takahashi; Toshiaki Akahane; Daisuke Yamamoto; Hideo Nakamura; Hiroki Sawa; Kazumi Nitta; Wataru Ide; Ikuo Hashimoto; Hajime Kamada
Journal:  Mol Clin Oncol       Date:  2014-05-05

Review 4.  Role of Positron Emission Tomography in Primary Central Nervous System Lymphoma.

Authors:  Laura Rozenblum; Caroline Houillier; Carole Soussain; Marc Bertaux; Sylvain Choquet; Damien Galanaud; Khê Hoang-Xuan; Aurélie Kas
Journal:  Cancers (Basel)       Date:  2022-08-23       Impact factor: 6.575

5.  Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma-a narrative review.

Authors:  Simone Krebs; Julia G Barasch; Robert J Young; Christian Grommes; Heiko Schöder
Journal:  Ann Lymphoma       Date:  2021-06-30

6.  The Potential Benefit by Application of Kinetic Analysis of PET in the Clinical Oncology.

Authors:  Mustafa Takesh
Journal:  ISRN Oncol       Date:  2012-12-26

Review 7.  18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma.

Authors:  Nobuyuki Kawai; Keisuke Miyake; Yuka Yamamoto; Yoshihiro Nishiyama; Takashi Tamiya
Journal:  Biomed Res Int       Date:  2013-06-17       Impact factor: 3.411

8.  18F-FDG-PET-based radiomics features to distinguish primary central nervous system lymphoma from glioblastoma.

Authors:  Ziren Kong; Chendan Jiang; Ruizhe Zhu; Shi Feng; Yaning Wang; Jiatong Li; Wenlin Chen; Penghao Liu; Dachun Zhao; Wenbin Ma; Yu Wang; Xin Cheng
Journal:  Neuroimage Clin       Date:  2019-06-27       Impact factor: 4.881

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.